Get started
Centessa Pharmaceuticals PLC ADRCentessa Pharmaceuticals PLC ADRCentessa Pharmaceuticals PLC ADR

Centessa Pharmaceuticals PLC ADR

No trades
See on Supercharts
OverviewFinancialsNewsDiscussionsForecastSeasonalsETFs

260 chart


Full chart

260 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.65 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.5 EUR
Net income (FY)
‪−227.83 M‬ EUR
Revenue (FY)
0.00 EUR
Shares float
‪85.14 M‬
Beta (1Y)
1.10

About Centessa Pharmaceuticals PLC ADR


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Saurabh Saha
Website
centessa.com
Headquarters
Altrincham
Founded
2020
ISIN
US1523091007
FIGI
BBG0118S87M8
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.

Check out other big names from the same industry as 260.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

260 news



Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.